Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

(Redirected from CAPRICORN)
Jump to navigation Jump to search

WikiDoc Resources for Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Articles

Most recent articles on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Most cited articles on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Review articles on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Articles on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Images of Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Photos of Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Podcasts & MP3s on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Videos on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Evidence Based Medicine

Cochrane Collaboration on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Bandolier on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

TRIP on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Clinical Trials

Ongoing Trials on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study at Clinical Trials.gov

Trial results on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Clinical Trials on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

NICE Guidance on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

NHS PRODIGY Guidance

FDA on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

CDC on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Books

Books on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

News

Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study in the news

Be alerted to news on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

News trends on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Commentary

Blogs on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Definitions

Definitions of Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Patient Resources / Community

Patient resources on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Discussion groups on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Patient Handouts on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Directions to Hospitals Treating Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Risk calculators and risk factors for Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Healthcare Provider Resources

Symptoms of Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Causes & Risk Factors for Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Diagnostic studies for Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Treatment of Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Continuing Medical Education (CME)

CME Programs on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

International

Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study en Espanol

Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study en Francais

Business

Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study in the Marketplace

Patents on Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Experimental / Informatics

List of terms related to Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]


CAPRICORN = Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study

Overview

A multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <40%.

It was not known whether beta blockers confer additional benefit when used in the context of modern post-MI management (eg, fibrinolytic therapy and primary percutaneous transluminal coronary angioplasty, aspirin, and angiotensin converting enzyme inhibitors).

Patients in CAPRICORN were treated with a maximum dose of 25 mg bid and observed until 633 validated primary end points had occurred. Because the overall mortality was lower than had been predicted, a co-primary end point was adopted that included the original primary end point (all-cause mortality) plus the first of the prespecified secondary end points (all-cause mortality or cardiovascular hospitalizations).

A significant 23% reduction in the original primary end point of all-cause mortality was observed. A total of 340 (35%) patients died or had a cardiovascular hospitalization in the carvedilol group versus 367 (37%) in the placebo group. Therefore, the revised primary end point of all-cause mortality or cardiovascular hospitalization was reduced by 8%, which was not statistically significant.

Significant reductions in cardiovascular mortality, nonfatal MI, and the combination of all-cause mortality or nonfatal MI were observed.

Although statistical significance for the revised primary end point was not reached, CAPRICORN has an important role in guiding future use of beta blockers in the early post-MI period.[1]

Reference

  1. Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)Am J Cardiol. 2004 May 6;93(9A):13B-6B.Click here to read

Template:WikiDoc Sources